| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/23/2014 | CN101890161B 聚核苷酸组合物佐剂 Polynucleotide adjuvant composition |
| 07/23/2014 | CN101854804B Hdac抑制剂 Hdac inhibitors |
| 07/23/2014 | CN101820875B 含有硫辛酸衍生物的药物制剂 Pharmaceutical preparations containing lipoic acid derivatives |
| 07/23/2014 | CN101653354B 化学物质的无创测量 Noninvasive measurement of chemical substances |
| 07/23/2014 | CN101643464B 用于抑制组织蛋白去乙酰酶的化合物 Compounds for inhibiting histone deacetylase |
| 07/23/2014 | CN101580510B 青蒿素类衍生物及其应用 Artemisinin derivatives and its application |
| 07/23/2014 | CN101460522B 糖基化抗体 Glycosylated ANTIBODY |
| 07/23/2014 | CN101454275B 口服生物可利用的咖啡酸相关的抗癌药 Orally bioavailable caffeic acid-related cancer drug |
| 07/23/2014 | CN101429189B 2，3-二取代芳基噻吩类衍生物及其用途 2,3-di-substituted aryl thiophene derivatives and use thereof |
| 07/23/2014 | CN101238149B 新抗igf-ir抗体及其用途 The new anti-igf-ir antibodies and their use |
| 07/22/2014 | US8785632 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| 07/22/2014 | US8785617 Oligomeric compounds for the modulation of HIF-1A expression |
| 07/22/2014 | US8785569 Drug carrier with chelating complex micelles and the application thereof |
| 07/22/2014 | US8785496 Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting |
| 07/22/2014 | US8785495 Compositions including beta-hydroxy-beta-methylbutyrate |
| 07/22/2014 | US8785448 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 07/22/2014 | US8785433 Quinoline derivatives as PI3 kinase inhibitors |
| 07/22/2014 | US8784862 Compounds and method for coating surfaces in a hemocompatible manner |
| 07/22/2014 | US8784824 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 07/22/2014 | US8784809 Vascular endothelial growth factor 2 |
| 07/22/2014 | US8784799 Duplexed parvovirus vectors |
| 07/22/2014 | US8784796 Vaccine immunotherapy for treating hepatocellular cancer in immune suppressed patients |
| 07/22/2014 | US8784772 Urothelial differentiation of urothelial carcinoma: a bladder cancer stem cell model |
| 07/22/2014 | CA2762960C Recrystallization processes for obtaining anhydrous optically active lansoprazole |
| 07/22/2014 | CA2748765C Compounds, compositions, and methods for preventing metastasis of cancer cells |
| 07/22/2014 | CA2582766C Isomigrastatin analogs in the treatment of cancer |
| 07/22/2014 | CA2570324C Rage fusion proteins and methods of use |
| 07/22/2014 | CA2537158C Cxcr4 antagonist and use thereof |
| 07/22/2014 | CA2412845C Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 07/22/2014 | CA2405299C Method of treatment using ligand-immunogen conjugates |
| 07/22/2014 | CA2388562C Mammalian cytokines; related reagents and methods |
| 07/22/2014 | CA2383774C Fibroblast growth factor-like polypeptides |
| 07/22/2014 | CA2376506C Neuromedin b and somatostatin receptor agonists |
| 07/21/2014 | CA2803215A1 Compositions and methods related to prostate cancer |
| 07/17/2014 | WO2014110574A1 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| 07/17/2014 | WO2014110555A1 Compositions and methods for treating cancer |
| 07/17/2014 | WO2014110503A1 Methods and compositions for treating cancer |
| 07/17/2014 | WO2014110443A1 Methods of treating pancreatic cancer |
| 07/17/2014 | WO2014110408A1 Method for treating cancer based on mutation status of k-ras |
| 07/17/2014 | WO2014110261A1 Cyp450 lipid metabolites reduce inflammation and angiogenesis |
| 07/17/2014 | WO2014110189A1 Deuterated momelotinib |
| 07/17/2014 | WO2014110154A1 Methods and comp0stions for treatment of demyelinating diseases |
| 07/17/2014 | WO2014108899A1 Fluorinated cbd compounds, compositions and uses thereof |
| 07/17/2014 | WO2014108858A1 Fatty acid synthase inhibitors |
| 07/17/2014 | WO2014108837A1 Combination |
| 07/17/2014 | WO2014108829A1 New antibody fragments, compositions and uses thereof |
| 07/17/2014 | WO2014108759A1 INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA |
| 07/17/2014 | WO2014108547A1 A peptide conjugate suitable for use as an anti-cancer agent |
| 07/17/2014 | WO2014108532A1 Modulators of the interaction of astrin and raptor, and uses thereof in cancer therapy |
| 07/17/2014 | WO2014108520A1 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases |
| 07/17/2014 | WO2014108456A1 Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patients |
| 07/17/2014 | WO2014107803A1 Gem-difluorinated c-glycoside compounds as anti-cancer agents |
| 07/17/2014 | WO2014081405A3 Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
| 07/17/2014 | WO2014070991A3 Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
| 07/17/2014 | WO2014062587A3 Injectable cancer compositions |
| 07/17/2014 | WO2013059885A3 Polypeptide constructs and uses thereof |
| 07/17/2014 | WO2012156532A8 Anti-human-her3 antibodies and uses thereof |
| 07/17/2014 | US20140200654 Drug-delivery endovascular stent and method of forming the same |
| 07/17/2014 | US20140199762 Immunotherapeutic Methods Using Epitopes of WT-1 and GATA-1 |
| 07/17/2014 | US20140199414 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
| 07/17/2014 | US20140199282 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 07/16/2014 | EP2755027A1 Modulators of the interaction of astrin and raptor, and uses thereof in cancer therapy |
| 07/16/2014 | EP2754718A1 Vascular endothelial myostatin mutant that mutates at atp binding sites |
| 07/16/2014 | EP2754682A1 Method for manufacturing block copolymer |
| 07/16/2014 | EP2754671A2 Anti MIF antibodies |
| 07/16/2014 | EP2754665A1 Peptide inhibiting matrix metalloproteanases activity and use thereof |
| 07/16/2014 | EP2754660A1 Pyridazinon derivatives |
| 07/16/2014 | EP2754659A1 4-substituted-(3-substituted-1h-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof |
| 07/16/2014 | EP2754656A1 Androgen receptor modulating compounds |
| 07/16/2014 | EP2754655A2 Novel compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same |
| 07/16/2014 | EP2754453A1 Conjugate of a cationic antimicrobial peptide and of a fatty acid for use as an anti-cancer agent |
| 07/16/2014 | EP2754451A1 The use of ache as nuclease |
| 07/16/2014 | EP2754441A2 Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
| 07/16/2014 | EP2753692A2 Microrna-based methods and assays for osteosarcoma |
| 07/16/2014 | EP2753646A1 Anti-cd40 antibodies, uses and methods |
| 07/16/2014 | EP2753635A1 P53 activating peptides |
| 07/16/2014 | EP2753628A1 Platinum anticancer agents |
| 07/16/2014 | EP2753616A1 Crystalline forms of afatinib di-maleate |
| 07/16/2014 | EP2753610A2 Crystalline forms of cabazitaxel |
| 07/16/2014 | EP2753361A1 Nanoparticle tumour vaccines |
| 07/16/2014 | EP2753360A1 Nanoparticle-peptide compositions |
| 07/16/2014 | EP2753348A1 A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate |
| 07/16/2014 | EP2753345A1 Polypeptide vaccine |
| 07/16/2014 | EP2753336A1 Compositions comprising s-adenosylmethionine and a gallic acid ester |
| 07/16/2014 | EP2753327A2 Amido compounds as ror-gamma-tmodulators and uses thereof |
| 07/16/2014 | EP2753322A1 Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide |
| 07/16/2014 | EP2753315A1 Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
| 07/16/2014 | EP2753313A1 Pharmaceutical compositions comprising an aromatase inhibitor |
| 07/16/2014 | CN1890221B 1-n-苯基-氨基-1h-咪唑衍生物和含有它们的医药组合物 1-n- phenyl - amino -1h- imidazole derivatives and pharmaceutical compositions containing them |
| 07/16/2014 | CN1638800B 抗cd30的人类单克隆抗体 The human monoclonal antibody anti-cd30 |
| 07/16/2014 | CN103930547A 用于治疗hsf1相关疾病的有机组合物 For the treatment of related diseases hsf1 organic composition |
| 07/16/2014 | CN103930443A 通过拮抗il-6受体抑制肿瘤生长的方法 Il-6 receptor by antagonizing the inhibition of tumor growth method |
| 07/16/2014 | CN103930442A 抗cd40抗体、用途和方法 Anti-cd40 antibodies, and methods of use |
| 07/16/2014 | CN103930441A 附加糖链的多肽和含有该多肽的医药组合物 Polypeptides and pharmaceutical compositions containing the oligosaccharide chain polypeptide |
| 07/16/2014 | CN103930427A 大环flt3 激酶抑制剂 Macrocyclic kinase inhibitors flt3 |
| 07/16/2014 | CN103930415A 泛素特异性蛋白酶7的选择性和可逆性抑制剂 Ubiquitin-specific protease selective and reversible inhibitor of 7 |
| 07/16/2014 | CN103930408A 用于癌症治疗的吗啉基苯并三嗪 For cancer treatment morpholine benzene and triazine |
| 07/16/2014 | CN103930407A 用作激酶活性调节剂的氨基嘧啶衍生物 Modulators of kinase activity is used as an amino pyrimidine derivative |
| 07/16/2014 | CN103930399A 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物 Di-substituted derivatives of 5-fluoro-pyrimidine containing imino sulfinyl group |
| 07/16/2014 | CN103930166A p62小分子化学抑制剂 small molecule chemical inhibitors of p62 |